Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5723623 | 1.00 | ADORA2A (0.83) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723603 | 0.95 | ADORA2A (0.91) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723596 | 0.95 | ADORA2A (0.91) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723502 | 0.94 | ADORA2A (0.82) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723564 | 0.94 | ADORA2A (0.82) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723466 | 0.93 | ADORA2A (0.91) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723460 | 0.93 | ADORA2A (0.91) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL725366 | 0.91 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6335151 | 0.91 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723936 | 0.90 | ADORA2A (0.89) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1255764-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2006-05-10 | — | — | EP | claimed |
| US-6525032-B2 | Agonists of human adenosine receptors useful as anti-inflammatory agents in treatment of diseases of respiratory tract; chemical intermediates | PFIZER INC | 2003-02-25 | — | — | US | claimed |
| US-20010020089-A1 | Purine derivatives | PFIZER INC. | 2001-09-06 | — | — | US | claimed |
| EP-1255764-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2006-05-10 | — | — | EP | disclosed |
| US-6525032-B2 | Agonists of human adenosine receptors useful as anti-inflammatory agents in treatment of diseases of respiratory tract; chemical intermediates | PFIZER INC | 2003-02-25 | — | — | US | disclosed |
| US-20010020089-A1 | Purine derivatives | PFIZER INC. | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020089-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.